Comparative efficacy and toxicity of brexucabtagene and lisocabtagene
| Agent . | ORR . | CRR . | Median follow-up (mo) . | mDOR (mo) . | mPFS (mo) . | mOS (mo) . | CRS. overall . | CRS > grade 2 . | Neurotoxicity, overall . | Neurotoxicity > grade 2 . |
|---|---|---|---|---|---|---|---|---|---|---|
| Brexu-cel (N = 68)10 | 91% | 68% | 35.6 | 28.2 | 25.8 | 46.6 | 91% | 15% | 63% | 31% |
| Liso-cel (N = 83)12 | 83% | 72% | 16.1 | 15.7 | 15.3 | 18.2 | 61% | 1% | 31% | 9% |
| Agent . | ORR . | CRR . | Median follow-up (mo) . | mDOR (mo) . | mPFS (mo) . | mOS (mo) . | CRS. overall . | CRS > grade 2 . | Neurotoxicity, overall . | Neurotoxicity > grade 2 . |
|---|---|---|---|---|---|---|---|---|---|---|
| Brexu-cel (N = 68)10 | 91% | 68% | 35.6 | 28.2 | 25.8 | 46.6 | 91% | 15% | 63% | 31% |
| Liso-cel (N = 83)12 | 83% | 72% | 16.1 | 15.7 | 15.3 | 18.2 | 61% | 1% | 31% | 9% |
CRR, complete response rate.